GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...

When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit the ...

GSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager for multiple myeloma from ...

GSK plc (NYSE:GSK) has reached two important regulatory milestones involving treatments for chronic hepatitis B and rectal cancer.

GSK said Chief Executive Emma Walmsley would step down and be succeeded by commercial chief Luke Miels, as the drugmaker works to replenish its product lineup. Walmsley will step down at the end of ...